Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Iptacopan in Patients With ANCA Associated Vasculitis
Iptacopan in Patients With ANCA Associated Vasculitis

NCT06388941

Active Not RecruitingPhase 2

Sponsor: Novartis Pharmaceuticals

Conditions: Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis

Interventions: Iptacopan, Placebo, Rituximab

Countries: United States, Argentina, Australia, Austria, Belgium, Canada, China, Czechia

The purpose of this study is to evaluate the efficacy and safety of iptacopan compared to standard of care (SOC) to induce and maintain remission in study participants with active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), when used in combination with rituximab (RTX) induction. The trial will also assess the impact of iptacopan on disease relapses, evolution of renal function and proteinuria, GC side effects, patients' immune status, and QoL.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Newly diagnosed or relapsed GPA and MPA (according to the 2022 ACR/EULAR classification criteria for GPA and MPA) requiring treatment with RTX and GC as per investigator's judgement.
* BVAS assessment with ≥1 major item, or ≥3 minor items, or ≥2 renal items at Screening.
* Positive antibody test for anti-proteinase 3 (PR3) or anti-myeloperoxidase (MPO) antibodies at Screening or with history of documented evidence of a positive antibody test.

Exclusion Criteria:

* Other systemic disease which constitutes the primary illness, including but not limited to: eosinophilic granulomatosis with polyangiitis (EGPA), moderate to severe systemic lupus erythematosus, IgA vasculitis (Purpura Schönlein-Henoch), rheumatoid vasculitis, Sjögren's syndrome, anti-glomerular basement membrane (GBM) disease, cryoglobulinemic vasculitis, autoimmune hemolytic anemia, autoimmune lymphoproliferative syndrome or mixed connective tissue disease.
* Alveolar hemorrhage requiring invasive pulmonary ventilation support at Screening.
* Severe kidney disease defined as estimated glomerular filtration rate (eGFR) \<15 mL/minute/1.73m2, or kidney failure defined as receiving renal replacement therapy such as hemo(dia)filtration, hemo-/peritoneal dialysis, or having received a kidney transplant.
* Received plasma exchange/-pheresis within 12 weeks prior to Screening.
Locations (42)
  • Mesa, Arizona, United States
  • Rochester, Minnesota, United States
  • CABA, Buenos Aires, Argentina
  • La Plata, Buenos Aires, Argentina
  • CABA, Argentina
  • Concord, New South Wales, Australia
  • Clayton, Victoria, Australia
  • Innsbruck, Tyrol, Austria
  • Graz, Austria
  • Vienna, Austria
  • Leuven, Vlaams Brabant, Belgium
  • Roeselare, West-Vlaanderen, Belgium
  • London, Ontario, Canada
  • Fleurimont, Quebec, Canada
  • Montreal, Quebec, Canada
  • Montreal, Quebec, Canada
  • Québec, Quebec, Canada
  • Shijiazhuang, Hebei, China
  • Zhengzhou, Henan, China
  • Beijing, China
  • Prague, Czechia
  • Aarhus N, Denmark
  • Herlev, Denmark
  • Angers, France, France
  • Brest, France
  • Dijon, France
  • Marseille, France
  • Paris, France
  • Toulouse, France
  • Kirchheim unter Teck, Baden-Wurttemberg, Germany
  • + 12 more on CT.gov